Atmo Biosciences is pleased to announce that the European Patent Office and IP Australia have each granted patents related to key intellectual property for Atmo’s ingestible gas sensor capsule, providing coverage until 2037. This follows the recent granting of the equivalent patent in the USA which was announced in September 2022.
READ MOREAtmo Biosciences is pleased to announce that it has successfully completed the audit of its Quality Management System to obtain ISO 13485:2016 accreditation.
READ MOREAtmo Biosciences is pleased to announce publication of a clinical study demonstrating strong agreement between data from Atmo’s world-first ingestible gas-sensing capsule and and a validated, FDA-cleared Wireless Motility Capsule (WMC), in determining transit metrics in healthy subjects.
READ MOREAtmo Biosciences is pleased to announce that the US Patent and Trademark Office (USPTO) has granted the patent for Atmo’s ingestible gas sensor capsule.
READ MOREAtmo Biosciences has appointed a Medical Advisory Board (MAB), comprising world-renowned gastroenterologists. The Atmo MAB consists of six gastroenterologists selected for their specialist expertise and interest in functional gut disorders and related conditions, many of which Atmo is targeting. The MAB members are highly regarded key opinion leaders in their respective fields and have extensive experience with wireless motility capsule technology.
READ MOREAtmo Biosciences Limited, a digital health company developing the world’s first ingestible gas-sensing capsule for monitoring gut health and microbiome function, has made three key appointments, further building capability at the executive and Board levels.
READ MORE